EVOK News and Press, Evoke Pharma Inc. From 04/02/19

SOLANA BEACH, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administ...

Advaxis (NASDAQ: ADXS ) +40%  on positive ADXS-NEO data . More news on: Advaxis, Inc., Pulmatrix, Inc., Evoke Pharma, Inc., Stocks on the move, Read more ...

Gainers: Atossa Genetics (NASDAQ: ATOS ) +242% . Hancock Jaffe Laboratories (NASDAQ: HJLI ) +41% . WageWorks (NYSE: WAGE ) +30%.  Smith Micro Software (NASDAQ: SMSI ) +31% . Akari Therapeutics (NASDAQ: AKTX ) +30% . KalVista Pharmaceuticals (NASDAQ: KALV ) +29% . MongoDB (NASDA...

Atossa Genetics (NASDAQ: ATOS ) +223%  on expanded access for Endoxifen. More news on: Atossa Genetics Inc., Hancock Jaffe Laboratories, Inc., Safe-T Group Ltd, Stocks on the move, Read more ...

Thinly traded nano cap Evoke Pharma (NASDAQ: EVOK ) is up  19%  premarket on modestly higher volume following its announcement that it has submitted its response to the FDA's multidisciplinary review (DR) letter related to its Gimoti marketing application. More news on: Evoke P...

SOLANA BEACH, Calif., March 14, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has submitted its response to the U.S. Food and Drug Administration’s (FDA)...

Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Evoke Pharma Tumbles After Preliminary NDA Review News: Recently, Evoke Pharma ( EVOK ) tumbled by 51% on the announcement that the FDA was not sat...

Evoke Pharma (NASDAQ: EVOK ): Q4 GAAP EPS of -$0.10 misses by $0.02. More news on: Evoke Pharma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Recently received multi-disciplinary review (DR) letter from U.S. Food and Drug Administration (FDA) for Gimoti™ 505(b)(2) New Drug Application (NDA) April 1, 2019 Prescription Drug User Fee Act (PDUFA) date maintained Company expects to hold a conference call at a later dat...

Aurora Cannabis (NYSE: ACB ) initiated with Outperform rating and $14 (94% upside) price target at Cowen and Company citing its large cultivation footprint and geographic diversity. Shares up  3%  premarket. More news on: Aurora Cannabis Inc., Gossamer Bio, Alnylam Pharmaceutical...